Acute Coronary SyndromeNCT05770323
Association Between Uric Acid and Acute Coronary Syndrome
An observational study of Acute Coronary Syndrome, run by Sohag University.
Trial summary
The aim of the study is to acess the association between admission serum uric acid level and in_hospital outcomes in patients with acute coronary syndromes Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Acute Coronary Syndrome
- What is being tested?
- Uric acid level
- How many people
- 150 participants
- Where
- No sites listed yet
- Study dates
- 22 Mar 2023to 22 Mar 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: All Patient admited to sohag University in CCU with acute coronary syndrome
Who may be able to join
- all patients with acute coronary syndrome with one of the Following
- Typical Chest pain
- ECG changes
- Elevated cardiac enzyme
Who cannot join
- patients aged less than 18 years
- patients with gout
- patients with treated with diuretics
- Patient with CKD
- Patient with chronic haemolytic anemia
Trial locations and contacts
No sites are listed yet.
Hassan A Hassanin contact
About this study
Official title: The Association Between Serum Uric Acid Level and Acute Coronary Syndrome in_hospital Outcomes
The aim of the study is to acess the association between admission serum uric acid level and in_hospital outcomes in patients with acute coronary syndromes
Read the detailed description
Prospective study
- To acess patients with acute coronary syndrome including one of (typical Chest pain _ECGchanges _elevated cardic enzyme)
- the complication occur in patients with hyperurecemia and those with normal uric acid
- Conditions
- Acute Coronary Syndrome
- Being tested
- Uric acid level
- Medical subject headings
- Acute Coronary Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Uric acid levelDiagnostic test
Uric acid will be measured for all Patients with acute coronary syndrome and result will be analysed
| Study group | Role | What they receive |
|---|---|---|
| Patients with normal uric acid levels | Patient with uric acid level (2.5_6)for femal and (3_7)for males Receives: Diagnostic Test: Uric acid level | |
| Patients with elevated uric acid level (hyperurecemia) | Uric acid level more than 7 for males and more than 6 for female Receives: Diagnostic Test: Uric acid level |
What is being measured
The primary outcome is the main question the study is designed to answer.
Association between serum uric acid level and acute coronary syndrome in hospital outcomes
Comparision between Patient with hyperurecemia and those with normal uric acid level
Measured: From the day of admission and 30 days post discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Mar 2023
- Study start22 Mar 2023 (estimated)
- Primary completion22 Feb 2024 (estimated)
- Study completion22 Mar 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Acute Coronary SyndromeStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hadeer Hassan Abdelaty, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05770323
- Sponsor's protocol ID
- Uric acid in ACSs
- Status last verified
- Mar 2023
- First submitted
- 22 Feb 2023
- Last updated
- 15 Mar 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Maloberti A, Biolcati M, Ruzzenenti G, Giani V, Leidi F, Monticelli M, Algeri M, Scarpellini S, Nava S, Soriano F, Oreglia J, Sacco A, Morici N, Oliva F, Piani F, Borghi C, Giannattasio C. The Role of Uric Acid in Acute and Chronic Coronary Syndromes. J Clin Med. 2021 Oct 16;10(20):4750. doi: 10.3390/jcm10204750.
PubMed 34682873
Study at a glance
From the registry record, last updated by the sponsor on 15 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Association Between Serum Uric Acid Level and Acute Coronary Syndrome in_hospital Outcomes
- ClinicalTrials.gov ID
- NCT05770323
- Acronym / sponsor ID
- Uric acid in ACSs
- Conditions
- Acute Coronary Syndrome
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 22 Mar 2023 (estimated)
- Primary completion
- 22 Feb 2024 (estimated)
- Study completion
- 22 Mar 2024 (estimated)
- First posted
- 15 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to acess the association between admission serum uric acid level and in_hospital outcomes in patients with acute coronary syndromes
Detailed description
Prospective study
- To acess patients with acute coronary syndrome including one of (typical Chest pain _ECGchanges _elevated cardic enzyme)
- the complication occur in patients with hyperurecemia and those with normal uric acid
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with normal uric acid levels | – | Diagnostic Test: Uric acid levelPatient with uric acid level (2.5_6)for femal and (3_7)for males |
| Patients with elevated uric acid level (hyperurecemia) | – | Diagnostic Test: Uric acid levelUric acid level more than 7 for males and more than 6 for female |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- All Patient admited to sohag University in CCU with acute coronary syndrome
Key inclusion criteria (4 listed)
- all patients with acute coronary syndrome with one of the Following
- Typical Chest pain
- ECG changes
- Elevated cardiac enzyme
Key exclusion criteria (5 listed)
- patients aged less than 18 years
- patients with gout
- patients with treated with diuretics
- Patient with CKD
- Patient with chronic haemolytic anemia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Uric acid levelUric acid will be measured for all Patients with acute coronary syndrome and result will be analysed | Diagnostic test | Patients with elevated uric acid level (hyperurecemia), Patients with normal uric acid levels |
Primary outcome
Association between serum uric acid level and acute coronary syndrome in hospital outcomes
Time frame: From the day of admission and 30 days post discharge
Comparision between Patient with hyperurecemia and those with normal uric acid level
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Mar 2023.
- Background: PubMed 34682873Maloberti A, Biolcati M, Ruzzenenti G, Giani V, Leidi F, Monticelli M, Algeri M, Scarpellini S, Nava S, Soriano F, Oreglia J, Sacco A, Morici N, Oliva F, Piani F, Borghi C, Giannattasio C. The Role of Uric Acid in Acute and Chronic Coronary Syndromes. J Clin Med. 2021 Oct 16;10(20):4750. doi: 10.3390/jcm10204750.
Related trials for Acute Coronary Syndrome
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
AI-Assisted Interpretation of Cardiac CT in the Emergency Department
Chest Pain, Acute Coronary Syndrome
Enrolling by invitation
Optical Coherence Tomography in Acute Vessel Evaluation
Ischemic Heart Disease, Ischemic Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hassan A Hassanin contact
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Coronary Syndrome, run by Sohag University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Hadeer H Abdelaty (01128222324, Hadirhassan@med.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Association between serum uric acid level and acute coronary syndrome in hospital outcomes (time frame: From the day of admission and 30 days post discharge). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05770323, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Mar 2023.